Free
Correspondence  |   August 2006
Systemic Thromboses after Cardiopulmonary Bypass: Is It Thrombin or Antithrombin?
Author Notes
  • Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Article Information
Correspondence
Correspondence   |   August 2006
Systemic Thromboses after Cardiopulmonary Bypass: Is It Thrombin or Antithrombin?
Anesthesiology 8 2006, Vol.105, 428-429. doi:
Anesthesiology 8 2006, Vol.105, 428-429. doi:
In Reply:—
I thank Drs. Tanaka and Sniecinski for their comments on our two reports of systemic thrombosis after cardiopulmonary bypass associated with aprotinin.1,2 They point out the possible role of antithrombin deficiency in these scenarios: This is applicable, given the settings of endocarditis, disseminated intravascular coagulation, and prolonged cardiopulmonary bypass.1,2 In the presence of antithrombin deficiency, overall thrombin production is increased.3 This thrombin excess could be a factor in the rapid development of systemic thrombosis described.1,2 
How do we integrate these observations into clinical practice? Clearly, we still lack adequate data to proceed. Bolus heparin therapy in the setting of aprotinin monitored with appropriate activated clotting time is an established standard for cardiopulmonary bypass, including deep hypothermic circulatory arrest, as the authors point out in their footnote. Furthermore, we have a large experience with this technique, including in deep hypothermic circulatory arrest.4–6 To my knowledge, there is no case report of this phenomenon with bolus heparin therapy titrated to heparin level. Of course, on the basis of case reports, no comparisons can be inferred between these two standards of care with respect to this kind of event.
Systemic thrombosis after cardiopulmonary bypass is very uncommon in the presence of standardized heparin therapy. It has also been reported in the pediatric population and in the presence of aminocaproic acid.7,8 A common feature in these reports is that the onset of thrombosis is shortly after heparin reversal with protamine, often in the setting of blood component transfusion to correct ongoing bleeding.
The exact etiology of this rare, but catastrophic event is probably multifactorial, including genetic factors such as factor V Leiden.9 Antithrombin deficiency may be another factor in this multifactorial etiology. The role of aprotinin is still to be elucidated, because there is recent evidence of an association with thrombotic risk after cardiopulmonary bypass.10 This area of endeavor is limited not only by a rare incidence and complex etiology, but also by a lack of real-time objective coagulation monitoring data. This information would allow analysis of the coagulation/anticoagulation imbalance to localize the lesion and direct further inquiry.
The role of antithrombin deficiency should also be interpreted in light of the thrombin inhibitor. Until recently, heparin, an indirect thrombin inhibitor, was the main anticoagulant for cardiopulmonary bypass. This will certainly shift in the future, given the arrival of bivalirudin, a direct thrombin inhibitor, as a clinical alternative to heparin for cardiac surgery with and without cardiopulmonary bypass.11,12 
Drs. Tanaka and Sniecinski have correctly highlighted antithrombin deficiency as a possible component in the etiology of systemic thrombosis after cardiopulmonary bypass. The continuing incidence of these rare, but catastrophic cases highlights the clinical necessity for better data, perhaps in the form of an international registry. This would provide a platform for further clinical trials to refine our coagulation management of cardiopulmonary bypass and improve perioperative outcomes for our patients.
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
References
Augoustides JG, Lin J, Gambone AJ, Cheung AT: Fatal thrombosis in an adult after thoracoabdominal aneurysm repair with aprotinin and deep hypothermic circulatory arrest. Anesthesiology 2005; 103:215–6Augoustides, JG Lin, J Gambone, AJ Cheung, AT
Augoustides JG, Kilbaugh T, Harris H, Glick JH, Acker M, Savino JS: Fatal thrombosis after mitral valve replacement for endocarditis: Aprotinin and disseminated intravascular coagulation (letter). Anesthesiology 2006; 104:213Augoustides, JG Kilbaugh, T Harris, H Glick, JH Acker, M Savino, JS
Tanaka KA, Szlam F, Katori N, Sato N, Vega JD, Levy JH: The effects of argatroban on thrombin generation and hemostatic activation in vitro  . Anesth Analg 2004; 99:1283–9Tanaka, KA Szlam, F Katori, N Sato, N Vega, JD Levy, JH
Augoustides JG, Floyd TF, McGarvey M, Ochroch EA, Pochettino A, Fulford S, Gambone AJ, Weiner J, Raman S, Savino JS, Bavaria JE, Jobes DR: Major clinical outcomes in adults undergoing thoracic aortic surgery requiring deep hypothermic circulatory arrest: Quantification of organ-based perioperative outcome and detection of opportunities for perioperative intervention. J Cardiothorac Vasc Anesth 2005; 19:446–52Augoustides, JG Floyd, TF McGarvey, M Ochroch, EA Pochettino, A Fulford, S Gambone, AJ Weiner, J Raman, S Savino, JS Bavaria, JE Jobes, DR
Appoo JJ, Augoustides JG, Pochettino A, Savino JS, McGarvey M, Cowie D, Gambone AJ, Harris H, Cheung AT, Bavaria JE: Perioperative outcome in adults undergoing elective deep hypothermic circulatory arrest with retrograde cerebral perfusion in proximal aortic arch repair: Evaluation of protocol-based care. J Cardiothorac Vasc Anesth 2006; 20:3–7Appoo, JJ Augoustides, JG Pochettino, A Savino, JS McGarvey, M Cowie, D Gambone, AJ Harris, H Cheung, AT Bavaria, JE
Augoustides JG, Pochettino A, Ochroch EA, Cowie D, McGarvey ML, Weiner J, Gambone AJ, Pinchasik D, Cheung AT, Bavaria JE: Clinical predictors for prolonged intensive care unit care stay in adults undergoing thoracic aortic surgery requiring deep hypothermic circulatory arrest. J Cardiothorac Vasc Anesth 2006; 20:8–13Augoustides, JG Pochettino, A Ochroch, EA Cowie, D McGarvey, ML Weiner, J Gambone, AJ Pinchasik, D Cheung, AT Bavaria, JE
Heindel SW, Mill MR, Freid EB, Valley RD, White GC II, Norfleet EA: Fatal thrombosis associated with a hemi-Fontan procedure, heparin-protamine reversal, and aprotinin. Anesthesiology 2001; 94:369–71Heindel, SW Mill, MR Freid, EB Valley, RD White, GC Norfleet, EA
Fanashawe MP: Shore-Lesserson L, Reich DL: Two cases of fatal thrombosis after aminocaproic acid therapy and deep hypothermic circulatory arrest. Anesthesiology 2001; 95:1525–7Fanashawe, MP Shore-Lesserson, L Reich, DL
Donahue BS: The response to activated protein C after cardiopulmonary bypass: Impact of factor V Leiden. Anesth Analg 2004; 99:1598–603Donahue, BS
Mangano DT, Tudor IC, Dietzel C, Multicenter Study of Perioperative Ischemia Research Group, Ischemia and Education Foundation: The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354:353–65Mangano, DT Tudor, IC Dietzel, C Multicenter Study of Perioperative Ischemia Research Group, Ischemia and Education Foundation,
Smedira N, Dyke CM, Koster A, Jurmann M, Bhatia DS, Hu T, McCarthy HL, Lincoff M, Spiess B, Aronson S: Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: The results of the Evolution-Off study. J Thorac Cardiovasc Surg 2006; 131:686–92Smedira, N Dyke, CM Koster, A Jurmann, M Bhatia, DS Hu, T McCarthy, HL Lincoff, M Spiess, B Aronson, S
Dyke CM, Smedira N, Koster A, Aronson S, McCarthy HL, Kirschner R, Spiess B: A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The Evolution-On study. J Thorac Cardiovasc Surg 2006; 131:533–9Dyke, CM Smedira, N Koster, A Aronson, S McCarthy, HL Kirschner, R Spiess, B